BMS-986141
- Generic Name
- BMS-986141
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H23N5O5S2
- CAS Number
- 1478711-48-6
- Unique Ingredient Identifier
- W530IRZ40G
- Background
BMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 58
- Registration Number
- NCT05093790
- Locations
- ๐ฌ๐ง
Local Institution - 0001, Edinburgh, United Kingdom
A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT02985632
- Locations
- ๐บ๐ธ
Clinical Pharmacology of Miami, Miami, Florida, United States
๐บ๐ธTexas Liver Institute, San Antonio, Texas, United States
๐บ๐ธClinical Research Center, Orlando, Florida, United States
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT02922452
- Locations
- ๐บ๐ธ
PPD Development, Austin, Texas, United States
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT02671461
- Locations
- ๐บ๐ธ
York Hospital, York, Pennsylvania, United States
๐บ๐ธBoston Medical Center, Boston, Massachusetts, United States
๐บ๐ธDuke University Medical Center, Durham, North Carolina, United States
Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 148
- Registration Number
- NCT02341638
- Locations
- ๐บ๐ธ
West Coast Clinical Trials, Llc, Cypress, California, United States
๐บ๐ธPpd Development, Lp, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.